Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant for Opioid/Stimulant Co-use in OUD
NCT05546515Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in opioid use disorder (OUD) and stimulant use disorder (SUD) comparing Suvorexant with Placebo (2 arms). Primary endpoints: Proportion of Positive Urine Drug Screens for Opioids at 30 days and Proportion of Positive Urine Drug Screens for Cocaine at 30 days. Started Dec 2022; status: completed.
02
Drugs
suvorexant
03
Conditions
opioid use disorder (OUD)stimulant use disorder (SUD)
Beyond the preview
Go deeper on NCT05546515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546515.